Section
Deals
M&A, licensing, and major transactions shaping the industry
DealsEndpoints News ↗
Ken Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in auto…
DealsFiercePharma ↗
Shortly after laying out $75 million upfront for Corstasis Therapeutics and its congestive heart failure edema…
DealsFierceBiotech ↗
Teva Pharmaceuticals has struck a deal to buy Emalex Biosciences for $700 million upfront, positioning the dru…
DealsBriefing
AstraZeneca resumes its shelved £300M UK expansion after rebate relief and a U.S.-U.K. pharma pact, signaling …
DealsFierceBiotech ↗
AbbVie has agreed to help finance a KRAS inhibitor from Kestrel Therapeutics in a deal that could hit up to $1…
DealsPharmaVoice ↗
Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and …
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.